Revenue Performance - Total revenue decreased by approximately $0.4 million, or 11.4%, to approximately $3.1 million for the fiscal year ended December 31, 2025, compared to $3.5 million in 2024[173]. - Revenue from virtual and hybrid events was approximately $2.7 million, accounting for 88.2% of total revenue, while physical events revenue increased to approximately $0.4 million, accounting for 11.8%[173]. - Revenue from hybrid, virtual, and physical events is recognized upon completion of the event, reflecting the consideration expected to be received[206]. - Revenue is recognized net of any taxes collected from customers, which are subsequently remitted to government entities[205]. Financial Losses - Net loss for the fiscal year ended December 31, 2025, was approximately $19.5 million, a significant increase from a net loss of approximately $3.0 million in 2024, representing a 557.3% increase[182]. - Selling, general and administrative expenses increased by approximately $9.9 million, or 183%, to approximately $15.3 million, largely due to non-cash expenses related to stock-based compensation[184]. Cash Flow and Liquidity - Operating cash outflows increased from approximately $2.5 million in 2024 to approximately $10.1 million in 2025, driven by higher operating expenses associated with the transition to a public company[194]. - Cash and cash equivalents at the end of the period increased to approximately $1.6 million as of December 31, 2025, compared to $0.05 million in 2024[189]. - The company had access to $18.0 million of liquidity through its ELOC as of December 31, 2025, to support ongoing operations[189]. Capital Expenditures and Obligations - Capital expenditures for the fiscal year ended December 31, 2025, were approximately $0.9 million, a slight decrease from $1.0 million in 2024[199]. - Total contractual obligations for future payments amounted to approximately $6.2 million as of December 31, 2025[197]. Accounting Policies and Estimates - The company applies ASC Topic 606 for revenue recognition, following a five-step model to determine the appropriate revenue amount[203]. - The transaction price for contracts is generally fixed at contract inception, based on agreed rates, and may differ from the final invoice amount[205]. - Management makes estimates regarding credit losses, useful lives of assets, and impairment of long-lived assets, which could differ from actual results[202]. Asset Management - Estimated useful lives for property and equipment include 7 years for computer and equipment, 10 years for furniture and fixtures, and leasehold improvements for the shorter of 10 years or lease term[209]. - Intangible assets consist of capitalized software, which is amortized on a straight-line basis over approximately five to seven years[210]. - Long-lived assets are reviewed for impairment whenever events indicate that carrying amounts may not be recoverable, with impairment losses recognized based on undiscounted cash flows[211]. Subcontractor Engagement - The company engages subcontractors for delivering events and assesses revenue on a gross basis, bearing the risk for services not fully paid by customers[208]. Market Risk Disclosures - The company does not provide quantitative and qualitative disclosures about market risk as it qualifies as a "smaller reporting company"[212].

Company Overview - The company is a pre-revenue, development-stage biopharmaceutical firm focused on developing new medicines for pain and neuropathy, having acquired Pharmagesic and its subsidiaries[22]. Product Development - The lead product candidate, Halneuron®, is in late-stage clinical development for chemotherapy-induced neuropathic pain (CINP), utilizing highly purified Tetrodotoxin (TTX) as its active ingredient[24]. - Halneuron® has shown a potential to reduce pain by modulating the Nav1.7 sodium channel, with a Phase 2 study indicating that 51% of patients experienced at least a 30% reduction in pain compared to 35% in the placebo group[34]. - The HAL-CINP-203 Phase 2b clinical trial commenced in Q1 2025, involving approximately 240 patients, with primary efficacy endpoints focused on pain improvement over 4 weeks[41]. - An interim analysis in December 2025 indicated that Halneuron® was separating from placebo in a subset of 97 patients, suggesting a statistically significant treatment effect[41]. - The overall dropout rate in the study was approximately 4.4%, significantly lower than typical rates for FDA-approved chronic pain medications[41]. Broader Research Strategy - The company is also exploring antiviral therapies for conditions like fibromyalgia and Long-COVID, indicating a broader research strategy beyond pain management[47]. - IMC-1 is a combination of famciclovir and celecoxib, with a Phase 3 program including two pivotal trials to demonstrate safety and efficacy in treating fibromyalgia (FM) patients[48]. - The Phase 3 studies will include a four-arm trial comparing IMC-1 to celecoxib, famciclovir, and placebo, and a two-arm study comparing IMC-1 to placebo[48]. - IMC-2, a combination of valacyclovir and celecoxib, is being developed for the treatment of long COVID (LC), with a Phase 2 study planned to assess fatigue improvement as a primary endpoint[50]. - The Phase 2 study for IMC-2 will be a randomized, double-blind trial lasting 12 weeks[50]. - SP16, a synthetic anti-inflammatory peptide, is in early Phase 1 development and aims to mitigate chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients[54]. - Preclinical studies of SP16 show it alleviates paclitaxel-induced neuropathy and promotes neuronal repair without interfering with chemotherapy efficacy[53]. Intellectual Property - The company holds 7 issued families of patents related to Halneuron® as of December 31, 2025, with exclusivity expiring between 2027 and 2030[59]. - The antiviral portfolio includes 14 issued patents related to IMC-1, with exclusivity extending to 2033[67]. Collaborations and Agreements - The company entered into a Know-How License Agreement with the University of Alabama in 2012, granting a 10% membership interest in exchange for a 25-year license to utilize herpesvirus-related technical information[76]. - An Exclusive Licensing Agreement was established with Serpin Pharma and Rejuvenation Labs on September 29, 2025, allowing the company a royalty-free, sublicensable global license for SP16 development[78]. - The company is collaborating with Serpin Pharma for the supply of SP16 for development research and potential commercialization[82]. Regulatory Environment - The FDA's review process for drug marketing approval typically takes about 10 months from the filing date of a standard NDA[91]. - The FDA may require a REMS plan to ensure that the benefits of a drug outweigh its risks, which can affect market potential and profitability[100]. - The FDA has various expedited review programs, including fast track and priority review, to accelerate the approval process for drugs addressing serious conditions[101][103]. - The FDA may grant accelerated approval to drugs for serious conditions that provide meaningful therapeutic advantages based on surrogate endpoints[108]. - Orphan drug designation can be granted for products intended to treat rare diseases affecting fewer than 200,000 individuals in the U.S.[113]. - Products with orphan status that receive the first FDA approval for their designated condition may obtain seven years of orphan product exclusivity[114]. - The FDA requires post-approval confirmatory studies for drugs granted accelerated approval to verify clinical benefits[112]. - Sales in the U.S. depend significantly on third-party payors' coverage and reimbursement decisions, which can be influenced by the cost-effectiveness of the products[121]. - Third-party payors may challenge pricing and restrict access to branded drugs if cheaper alternatives are available[122]. - The FDA imposes strict regulations on marketing, labeling, and promotion of approved products, with significant penalties for non-compliance[120]. - The Hatch-Waxman Amendments established an abbreviated approval process for generic drugs that are bioequivalent to previously approved drugs[129]. - The FDA may withdraw drug approvals if compliance with regulatory standards is not maintained post-marketing[119]. Financial Overview - The company completed a reverse stock split, converting every 25 shares of common stock into one share, effective October 7, 2024[149]. - In a registered direct offering on March 12, 2025, the company sold 578,950 shares of common stock at $8.26 per share, raising approximately $4.78 million in gross proceeds[151]. - The company raised approximately $12.5 million in gross proceeds from the January 2026 Offering, with net proceeds of approximately $11.4 million after deducting fees and expenses[160]. - As of December 31, 2025, the Company reported consolidated net losses of $34,257,370 and an accumulated deficit of $108,076,316[168]. - The Company has incurred losses since inception and anticipates continuing to incur significant additional operating losses for the foreseeable future[169]. - The Company requires additional capital to fund operations and may face challenges in obtaining necessary financing[171]. - The Company has not yet commercialized any products and has never generated revenue from product commercialization[168]. Clinical Trials and Challenges - The ongoing research and development activities will depend on the successful completion of clinical trials and regulatory approvals[183]. - The Company is heavily dependent on the success of its product candidates, Halneuron® and SP16, which are still under clinical development[183]. - The company faces significant challenges in obtaining regulatory approval for its product candidates, which is essential for generating sufficient revenue and funding future developments[184]. - Clinical trials are expensive and time-consuming, with outcomes that are inherently uncertain, leading to potential delays and failures[193]. - The company may face operational disruptions due to infectious disease outbreaks, impacting supply chains and clinical trial progress[190]. - Regulatory authorities may impose restrictions or require additional studies if safety issues arise, which could adversely affect commercialization efforts[187]. - Changes in regulatory policies could delay or prevent product approvals, impacting the company's ability to achieve profitability[188]. - The company must demonstrate substantial evidence of safety and efficacy through well-controlled clinical trials to gain regulatory approval[199]. - Adverse side effects or serious events during clinical trials could lead to interruptions or delays in the approval process[210]. Market Potential and Risks - The market opportunities for Halneuron® and SP16, if approved, may be smaller than anticipated, with potential target populations being small, which could hinder profitability without additional marketing approvals[215]. - The company has never obtained marketing approval for a product candidate, and there is a risk that the FDA may refuse to accept or approve any NDAs submitted, potentially delaying commercialization[216]. - Any delay in obtaining marketing approvals could prevent the company from commercializing product candidates, generating revenues, and achieving profitability[217]. - Even with FDA approval in the United States, the company may face challenges in obtaining approval in other jurisdictions, limiting global market potential[218]. - Regulatory approval processes vary significantly between jurisdictions, which could lead to increased costs and delays in product introduction[221]. - The company may be required to implement a Risk Evaluation and Mitigation Strategy (REMS) if side effects are identified, which could complicate marketing efforts[219]. - Undesirable side effects identified post-approval could lead to withdrawal of approvals, additional warnings, or restrictions on marketing[213]. - The company may face legal liabilities for harm caused to patients, which could impact its reputation and competitiveness[219]. - Regulatory authorities may impose additional testing requirements for changes to approved products, affecting the company's ability to adapt and innovate[219]. - The company lacks experience in obtaining regulatory approval in international markets, which could further limit market potential[221].

Financial Performance - The company incurred net losses of $140.1 million and $160.9 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $716.3 million as of December 31, 2025[169]. - The company has no products approved for commercial sale and has not generated any product revenue to date, indicating a high degree of uncertainty in evaluating its future success[168]. - The company anticipates significant expenses and operating losses for the foreseeable future, particularly as it progresses its product candidates through preclinical and clinical development[171]. - The company has devoted substantially all financial resources to research and development activities and does not expect to generate revenue from product sales for several years[170]. - The company may require substantial additional capital to finance operations and may be forced to delay or reduce research and drug development programs if unable to raise funds[173][179]. - The company has no current revenue and may need additional funding through equity or debt financing to continue operations[207]. Regulatory Environment - The company is subject to significant regulatory oversight by the FDA and other bodies, which may lengthen the regulatory review process and increase development costs[191]. - The regulatory approval process for the company's novel AAV genetic medicine technology is expected to be more expensive and time-consuming than for other therapeutic modalities, adding to development uncertainty[188]. - The company must comply with regulatory guidelines, and failure to do so may result in delays or discontinuation of product candidate development[194]. - The company has not commenced any regulatory approval applications, which may impede the ability to launch therapies[221]. - Even if regulatory approval is obtained, products will remain subject to ongoing regulatory scrutiny and compliance requirements[271]. - The company may seek accelerated approval for product candidates, but there is no assurance that such applications will be accepted or granted in a timely manner[270]. - Regulatory authorities may impose limitations on approved products, including narrow indications or additional post-marketing studies[268]. - The company anticipates that future healthcare legislation may increase the difficulty and cost of obtaining marketing approvals and affect pricing strategies[295]. Clinical Development - The company initiated Phase 3 studies for wet AMD in 2025, comparing a single dose of 4D-150 at 3E10 vg/eye to on-label aflibercept at 2mg Q8 weeks[209]. - The ability to generate revenue and achieve profitability depends on successful clinical trials, regulatory approvals, and market acceptance of product candidates[204]. - The company may encounter substantial delays in clinical trials due to various factors, including patient enrollment challenges and regulatory requirements[209]. - Limited patient pools for rare genetic diseases may hinder enrollment in clinical trials, affecting statistical significance and regulatory approval[216]. - The need for additional clinical trials may arise if initial trials do not meet statistical significance or safety requirements, delaying regulatory approval[231]. - Clinical trial delays could increase costs and jeopardize the ability to generate revenue, potentially harming the business[213]. Market and Competition - The company faces substantial competition from major pharmaceutical and biotechnology companies, which may hinder its ability to develop and commercialize products successfully[239]. - Competitors include established companies with significant financial resources, making it challenging for the company to gain market acceptance for its product candidates[240]. - The commercial success of genetic medicine product candidates may be adversely affected by public perception regarding safety and ethics, impacting capital raising and strategic agreements[195]. - The company may struggle to establish sales and marketing capabilities, which are crucial for the successful commercialization of approved products[243]. Manufacturing and Supply Chain - Manufacturing gene therapies is complex, and any production problems could delay development or commercialization efforts, impacting the company's business[250]. - The company must comply with cGMP regulations to obtain regulatory approval for its manufacturing processes, and any non-compliance could lead to significant delays[256]. - The company currently relies on third parties for the production of some planned clinical trial drugs and commercial drug materials, which limits control over certain aspects of manufacturing activities[259]. - The company depends on third-party suppliers for key raw materials, and any loss of these suppliers could seriously harm its business[263]. - Any contamination in the manufacturing process or shortages of raw materials could result in delays in research studies and clinical development[261]. Intellectual Property - The company holds five granted patents and two pending patent applications, with some patents being subject to government march-in rights, which could allow the government to license these patents to third parties under certain conditions[336]. - The patent application process is expensive and time-consuming, with no assurance that all necessary patents will be obtained or enforced effectively, which could limit competitive advantages[339]. - The company may face challenges in enforcing patent rights, as detecting infringement can be difficult, and legal proceedings could risk invalidating patents[342]. - The degree of future protection for proprietary rights is uncertain, and there is no guarantee that patents will provide sufficient protection against competitors[344]. - The company may not have control over the prosecution of patents licensed from third parties, which could affect the enforcement of those patents[345]. Compliance and Legal Risks - The company is subject to healthcare regulatory laws that could expose it to penalties, affecting business operations and relationships with stakeholders[318]. - Compliance with healthcare laws may involve substantial costs, and violations could lead to damages, fines, and exclusion from government-funded healthcare programs[321]. - The company relies on third parties for clinical trials and research, which may lead to delays in product development if these parties do not meet their contractual obligations[325]. - The company is responsible for ensuring compliance with Good Clinical Practice (GCP) in clinical trials, and failure to do so could result in fines and adverse publicity[326]. Economic and Legislative Factors - The Inflation Reduction Act of 2022 requires manufacturers to negotiate drug prices with Medicare, with the first negotiated prices effective in 2026 for ten drugs and in 2027 for an additional fifteen drugs[300]. - The One Big Beautiful Bill Act, enacted in July 2025, is expected to significantly reduce Medicaid funding, potentially decreasing enrollment and adversely affecting sales of new product candidates[301]. - Increased scrutiny over drug pricing has led to Congressional inquiries and proposed legislation aimed at enhancing transparency and reducing prescription drug costs, which could impact the pharmaceutical industry[303]. - Individual states are implementing regulations to control pharmaceutical pricing, including price caps and patient reimbursement constraints, which may adversely affect product demand and pricing[304]. - The company anticipates that future healthcare reforms may impose stricter coverage and payment criteria, leading to downward pressure on drug prices and potentially harming revenue generation[306].

Financial Performance - The company generated $7.3 million in royalty and licensing revenue for the year ended December 31, 2025, compared to $0.6 million in 2024[365]. - Total revenue for the year ended December 31, 2025, was $7.3 million, a significant increase from $0.6 million in 2024, representing a change of $6.7 million[387]. - Other income for 2025 was $25.0 million, primarily due to a $21.0 million unrealized gain on a long-term equity investment, compared to $35.5 million in 2024[391]. - The net loss for the year ended December 31, 2025, was $17.4 million, an improvement from a net loss of $26.4 million in 2024, showing a reduction of $9.0 million[393]. - The company has an accumulated deficit of $321.7 million as of December 31, 2025, with working capital of $66.1 million[393]. Funding and Capital - The company raised net proceeds of $350.5 million from the sale of capital stock as of December 31, 2025[365]. - The company received initial net proceeds of $75.1 million from the 2025 Private Placement, with potential additional gross proceeds of up to $94.0 million from warrant exercises[368]. - The company plans to use net proceeds from the 2026 Private Placement to support the development of OV329 into additional indications, including TSC and IS[373]. - The company anticipates gross proceeds of $60.0 million from the 2026 Private Placement, expected to close on March 19, 2026[374]. - The company raised $75.1 million in net proceeds from the 2025 Private Placement, with potential additional gross proceeds of up to $94.0 million from warrant exercises[394]. - The company expects to receive gross proceeds of $60.0 million from the 2026 Private Placement, aimed at supporting the development of OV329 and general R&D expenses[396][397]. Expenses and Cash Flow - Research and development expenses decreased to $25.6 million in 2025 from $36.8 million in 2024, a reduction of $11.2 million, primarily due to the pause of the OV888 program[388]. - General and administrative expenses were $24.1 million in 2025, down from $25.7 million in 2024, reflecting a decrease of $1.6 million[390]. - Net cash used in operating activities was $38.3 million for the year ended December 31, 2025, compared to $56.0 million for the year ended December 31, 2024[407]. - Net cash used in investing activities was $49.9 million for the year ended December 31, 2025, primarily related to purchases of investments in U.S. treasuries[408]. - Net cash provided by financing activities was $75.2 million for the year ended December 31, 2025, comprised of net proceeds from the 2025 Private Placement and other sources[409]. Assets and Securities - As of December 31, 2025, total cash, cash equivalents, and marketable securities amounted to $90.4 million, an increase from $53.1 million in 2024[392]. - As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $90.4 million[421]. - The company intends to maintain its portfolio of cash equivalents and marketable securities in institutional market funds to minimize risk[421]. - An immediate 100 basis point change in interest rates would not have a material effect on the fair market value of cash equivalents and marketable securities[421]. Business Outlook and Risks - The company expects significant expenses and operating losses to continue for several years as it advances drug candidates through clinical trials and builds a sales infrastructure[366]. - The company is subject to significant risks, including economic conditions, regulatory approval challenges, and competition in the pharmaceutical industry[375]. - The company has no products approved for commercial sale and anticipates financing future cash needs through equity offerings, debt financings, and collaborations[400]. Product Development - The company has developed a differentiated pipeline of drug candidates targeting brain disorders, with one program in clinical trials and another expected to begin in the first half of 2026[363]. - The company holds a portfolio of direct activators of potassium-chloride cotransporter 2 (KCC2), which is believed to be unique in the industry[363].

Tenant Composition and Market Dynamics - The tenant base in terms of Gross Leasable Area (GLA) is primarily composed of companies in Consumer Goods Distribution (37.4%), Retail (23.7%), and Third-Party Logistics (31.3%) as of December 31, 2025[88]. - The performance of the real estate markets is cyclical and tied to the U.S. economy and the economies of Costa Rica, Colombia, Peru, and Mexico[76]. - The company’s financial performance is significantly influenced by macroeconomic conditions and specific market dynamics within the industrial and logistics real estate sector[75]. - The revenues from operations in Colombia accounted for approximately 19.4% of total revenues for the year ended December 31, 2025[172]. - The company may experience reduced demand for properties due to adverse economic conditions, including inflation and currency devaluation in the countries of operation[194]. Financial Risks and Debt Management - 26.1% of the company's outstanding indebtedness bore fixed interest rates as of December 31, 2025, compared to 63.2% in 2024[84]. - The company is exposed to fluctuations in interest rates, which can increase borrowing costs and affect project profitability[82]. - As of December 31, 2025, the company's total outstanding debt was $295.3 million, which may impact cash flows and expose properties to foreclosure risks[102]. - The current interest rate environment poses risks for covenant breaches, potentially impacting future financing and overall business prospects[109]. - The company may incur additional indebtedness for strategic acquisitions, which could significantly increase financial obligations and affect debt servicing capabilities[103]. Operational and Market Challenges - Increased vacancy rates and inability to lease properties on favorable terms could negatively impact revenue streams[79]. - The company faces risks from economic downturns in specific sectors, which could adversely affect its operations and financial condition[88]. - Competition from larger investors and developers in the industrial real estate sector may lead to lower occupancy rates and rental income[95]. - The company faces increased competition in the rental market, which may lead to higher vacancy rates and downward pressure on rental rates, adversely affecting financial performance[98]. - The company’s ability to respond to economic downturns is limited due to fixed costs that do not decrease in unfavorable market conditions[77]. Construction and Development Risks - The average construction costs for warehouse projects in Colombia increased by 4.09% in 2025 and 4.28% in 2024, impacting project budgets and profitability[124]. - The engineering, design, and construction phases of new projects typically require nine to twelve months, while improvements to existing properties require one to three months[125]. - The company faces risks related to supply chain issues, which can lead to increased lead times and back-ordered products, affecting construction timelines[126]. - The company may experience material delays or expenses due to the inability to obtain necessary governmental approvals, licenses, and permits, which could adversely affect operations[127]. - The company may incur additional costs due to construction defects or delays, which could materially affect financial results[125]. Legal and Regulatory Risks - The company is subject to legal risks concerning the maintenance and acquisition of necessary governmental approvals, which can disrupt business activities[131]. - The company may face unexpected legal fees or loss of properties due to eminent domain actions by governments in the countries where it operates[138]. - The company is exposed to risks related to labor, health, and safety regulations, which could lead to penalties if violations occur[259]. - The company anticipates increased regulatory scrutiny regarding environmental laws in the countries it operates, which could materially affect its financial performance[261]. - LPA may face liabilities for environmental remediation costs, particularly in Colombia, Peru, and Mexico, where it could be jointly liable with tenants for soil pollution[263]. Competition and Market Position - The company may face significant competition for properties that meet its investment criteria, impacting acquisition activities and financing[144]. - The company is focused on premium assets (Class A Real Estate), which may narrow its target market and affect growth if demand decreases[149]. - The company may need to divest properties at below market terms to increase liquidity, which could adversely impact financial condition and growth prospects[152]. - Complications in relationships with local communities can adversely affect business continuity, reputation, liquidity, and results of operations[163]. - The company may strategically dispose of properties to redeploy capital into more advantageous real estate investment opportunities, affected by market conditions[151]. Corporate Governance and Shareholder Concerns - LPA's directors and officers collectively own or control 83.5% of the total voting power of the outstanding Ordinary Shares, giving them substantial influence over corporate actions[227]. - LPA incurs significant additional costs as a public company, including legal, accounting, and compliance expenses, which are expected to continue increasing[231]. - The company may require additional capital and may sell more Ordinary Shares or incur debt, leading to further dilution for shareholders[226]. - LPA's management team has limited experience operating a U.S. public company, which may affect compliance with regulatory obligations[233]. - LPA's current corporate governance practices allow it to operate with a board that does not require a majority of independent directors, which may afford less protection to shareholders[248]. Economic and Geopolitical Factors - The ongoing war between Russia and Ukraine and other geopolitical conflicts may lead to significant market disruptions and increased fuel costs[182]. - Political instability in Venezuela may contribute to regional uncertainty affecting assets in Latin America, including Costa Rica, Colombia, Peru, and Mexico[183]. - Increases in prices of energy, raw materials, and wages due to inflation could materially impact development and operating costs[186]. - The company faces risks from foreign exchange fluctuations, particularly with currencies like the Colombian peso, which could affect profitability when measured in U.S. dollars[172]. - Economic developments in the U.S. could adversely affect the economies of Costa Rica, Colombia, Peru, and Mexico, impacting the company's financial condition and market price of shares[205]. Tax and Compliance Risks - The company is subject to evolving tax regulations in Costa Rica, Colombia, Peru, and Mexico, which could lead to increased tax liabilities and adversely affect cash flow[203]. - The Cayman Islands' Economic Substance Act may impose compliance obligations on LPA, with potential financial penalties for non-compliance[235]. - LPA's reliance on exemptions from certain SEC reporting requirements may make its Ordinary Shares less attractive to investors, potentially affecting market activity and share price volatility[251]. - If LPA loses its status as a "foreign private issuer," it will incur substantial costs to comply with U.S. regulatory requirements, including filing periodic reports and financial statements[247]. - LPA is subject to various international laws and regulations, including anti-corruption and anti-money laundering laws, which could result in substantial fines or operational restrictions if violated[253].

Financial Performance - The company reported net sales of $164.7 billion in fiscal 2025, with net earnings of $14.2 billion, equating to $14.23 per diluted share[170]. - Cash flow from operations for fiscal 2025 was $16.3 billion, with $9.2 billion allocated to cash dividends and $5.0 billion used to repay long-term debt[171]. - Return on Invested Capital (ROIC) was 25.7% for fiscal 2025, down from 31.3% in fiscal 2024, primarily due to higher average equity and long-term debt from acquisitions[173][197]. - Net sales for fiscal 2025 increased by $5.2 billion, or 3.2%, to $164.7 billion, driven by acquisitions of SRS and GMS, which contributed approximately $6.3 billion in incremental net sales[183]. - Gross profit rose by $1.6 billion, or 2.9%, to $54.9 billion, with a gross profit margin of 33.3% in fiscal 2025 compared to 33.4% in fiscal 2024[189]. - Selling, General & Administrative (SG&A) expenses increased by $2.0 billion, or 6.8%, to $30.7 billion, representing 18.6% of net sales in fiscal 2025[190]. - Diluted earnings per share decreased to $14.23 in fiscal 2025 from $14.91 in fiscal 2024, impacted by lower net earnings[194]. - Comparable sales increased by 0.3% in fiscal 2025, with a 1.4% rise in comparable average ticket offset by a 1.0% decline in comparable customer transactions[187]. - Online sales accounted for 15.9% of net sales in fiscal 2025, increasing by 8.7% compared to fiscal 2024[185]. Capital Expenditures and Investments - In fiscal 2025, The Home Depot invested $3.7 billion in capital expenditures to support its growth strategy, including building new stores and enhancing customer experience[23]. - Home Depot plans to invest about $4 billion in fiscal 2026, representing approximately 2.5% of projected net sales[202]. - The company has made significant investments in associate compensation, including increased equity awards and profit-sharing programs for hourly associates in fiscal 2025[65]. - The company has automated and mechanized its rapid deployment center network to improve efficiency and product movement[50]. - Home Depot has invested in AI tools to enhance search, recommendations, and customer support features, contributing to higher traffic and sales growth[43]. Store Operations and Expansion - The company operates 2,359 stores across the U.S., Canada, and Mexico, with an average store size of approximately 104,000 square feet[17]. - Home Depot plans to open approximately 80 new stores over a five-year period, with 12 new stores opened in fiscal 2025[44]. - The company opened ten new stores in the U.S. and two in Mexico, bringing the total store count to 2,359 as of February 1, 2026[174]. - At the end of fiscal 2025, the company had a total of 2,035 U.S. store locations[147]. Customer Engagement and Experience - The company focuses on enhancing its interconnected shopping experience, investing in mobile applications and websites to improve customer engagement[41]. - The Home Depot serves two primary customer groups: DIY customers and Pros, with tailored approaches to meet their diverse needs[25][26]. - Approximately 50% of U.S. online orders were fulfilled through a store in fiscal 2025[52]. - Home Depot's mobile application provides store-specific maps and enhanced navigation tools to improve the in-store shopping experience[44]. - Investments in technology, such as Computer Vision, have improved product availability on shelves, driving higher customer satisfaction[44]. Supply Chain and Distribution - The Home Depot acquired SRS in fiscal 2024 and GMS in fiscal 2025, expanding its distribution capabilities to over 1,250 locations across the U.S. and Canada[18]. - The company’s supply chain initiatives aim for fast, reliable delivery, with same-day or next-day delivery options available in many markets[51]. - The company’s supply chain includes sourcing operations in multiple countries, ensuring compliance with responsible sourcing standards[35]. - The company has a vendor risk management program that assesses service provider risk based on data type accessed and/or retained[139]. Risks and Challenges - The company faces intense competition from various retailers, including traditional and online competitors, which could impact pricing and market share[77]. - The company must adapt to evolving customer expectations regarding delivery options, including faster and more reliable services, to maintain demand for its products[82]. - The company’s aging store base requires ongoing investment and maintenance to meet customer expectations for shopping experiences[85]. - The company’s ability to effectively respond to changing customer preferences and trends is critical for maintaining market share and customer relationships[81]. - Disruptions in the supply chain, exacerbated by events like the COVID-19 pandemic, have impacted the company's ability to meet customer demand, resulting in lost sales and increased costs[94]. - Labor shortages in distribution and fulfillment centers have been experienced, which may affect product availability and flow to stores and customers[96]. - The company faces risks related to cybersecurity, including potential data breaches and attacks that could compromise customer and business information[99]. - Increased online purchasing demand has strained fulfillment operations, leading to delays and higher out-of-stock levels[95]. - The company must continuously adapt to evolving customer preferences and technological advancements to maintain a competitive edge in the retail market[93]. Compliance and Regulatory - Compliance with government regulations has not materially impacted the company’s operations or competitive position[69]. - The company is focused on compliance with consumer-protection laws, which may increase administrative expenses and litigation risks[127]. - Regulatory uncertainties surrounding strategic transactions could lead to additional costs or delays, affecting anticipated outcomes[88]. - Changes in laws and regulations could increase the company's costs of doing business, impacting sales and profitability[125]. - Responsible sourcing standards must be upheld by suppliers to avoid legal and reputational risks, with potential consequences for non-compliance[118]. Community and Sustainability - The company is committed to sustainability, focusing on responsible sourcing and reducing environmental impact across its operations and supply chain[67]. - The company’s community support initiatives include the Home Depot Foundation, which aids U.S. veterans and communities affected by natural disasters[68].

Economic and Market Risks - Economic uncertainty and geopolitical instability could harm the company's financial condition and results of operations[144]. - The company may be adversely affected by inflation, which could increase overall costs and impact pricing strategies[154]. - The market for high-performance computing products is developing and may not grow as expected, affecting demand and sales[155]. - Supply chain disruptions could adversely affect the company's ability to obtain critical parts at reasonable prices, impacting profitability[144]. - Changes in U.S. government priorities and defense spending could negatively impact the company's financial position and results of operations[144]. - Demand for the company’s products may be affected by changes in customer budgets and delays in purchasing cycles, as well as the timing of product releases by competitors[161]. - The ongoing commoditization of HPC hardware and software is leading to increased pricing pressure, which may negatively impact operating results[211]. - Changes in export and import regulations could impair the company's ability to compete in international markets and lead to significant penalties for non-compliance[227]. Customer and Supplier Concentration - A limited number of customers represent a significant portion of sales, and the loss of any key customers could lead to a substantial decrease in revenue[144]. - In the year ended December 31, 2025, 61% of total revenues were attributable to the top three customers, up from 40% in 2024[188]. - Suppliers representing over 10% of total parts purchases accounted for approximately 34% and 68% of materials purchased in 2025 and 2024, respectively[191]. - The company relies on a limited number of parts suppliers, which poses risks to manufacturing and design processes[144]. - The company relies on a limited number of suppliers for critical components, particularly high-performance processors and GPUs, which could impact manufacturing capabilities[190]. Operational Challenges - The company's operating results may fluctuate significantly, making future predictions difficult and potentially leading to lower-than-expected performance[158]. - The company faces fluctuations in operating results due to various uncontrollable factors, including economic environments and competition, which may lead to significant variations in quarterly and annual results[159]. - Cybersecurity risks and incidents could disrupt operations and expose the company to significant liabilities[144]. - The company may face challenges in retaining and attracting key personnel, which could hinder effective business plan implementation[145]. - Recruitment and retention of key personnel is competitive, and failure to attract skilled employees could hinder business objectives[209]. - The sales cycles for some products can take several months or longer, increasing the risk of inventory becoming obsolete[200]. Regulatory and Compliance Risks - The company is subject to procurement laws and regulations that could affect its ability to conduct business with the U.S. government, including risks associated with contract terminations[181]. - The company’s ability to maintain profitability may be affected by changes in government procurement policies, which could create pricing pressure and increase costs[184]. - The company's contracts with the U.S. government are contingent upon Congressional appropriations, which may lead to risks of reduced orders or program cancellations if appropriations are delayed[178]. - Evolving regulations regarding artificial intelligence may impact demand for the company’s products, as they are often incorporated into AI-enabled platforms[175]. - Compliance with evolving data protection regulations, such as GDPR and CCPA, may result in increased costs and potential liabilities[222][223]. - The company may face unanticipated costs or liabilities due to new regulations or changes in existing regulations related to suppliers' products, impacting business operations[228]. Financial and Stock Market Considerations - The company has never paid cash dividends and does not expect to do so in the foreseeable future, focusing instead on retaining earnings for operational expansion[249]. - The company qualifies as a "smaller reporting company," allowing it to take advantage of reduced reporting requirements, which may affect the attractiveness of its common stock to investors[250]. - Future equity issuances could lead to dilution for current shareholders, impacting the market price of the common stock[236]. - The company may seek additional capital through equity offerings or debt financings, which could impose restrictions on operations and affect financial conditions[248]. - The market price of the company's common stock could decline if analysts issue adverse opinions or cease coverage[235]. - The company's common stock is subject to significant price volatility, influenced by various factors including market conditions and operating performance of technology companies[231]. - Anti-takeover provisions in the company's charter may hinder potential acquisitions and affect stockholder influence over management decisions[242]. - The company is authorized to issue up to 10,000,000 shares of preferred stock, which could have rights that adversely affect common stockholders[240]. - The company may face challenges in raising capital on acceptable terms, which could limit its ability to develop new technologies and expand operations[247]. Intellectual Property and Cybersecurity Risks - The company is exposed to significant risks regarding the protection of its intellectual property, which could harm its competitive position if not adequately safeguarded[213]. - Cybersecurity breaches pose a risk of theft of proprietary designs, potentially impacting the company's competitive edge and financial results[215]. - The company is obligated to indemnify channel partners and end-customers for certain intellectual property infringement claims, which could lead to substantial costs[220].

Financial Performance - Adjusted Free Cash Flow for the year ended December 31, 2025, was $190.69 million, an increase from $90.60 million in 2024, but a decrease from $203.92 million in 2023[27]. - The company reported net cash generated from operating activities of $415.46 million for 2025, a significant recovery from a cash outflow of $32.78 million in 2024[27]. - Capital expenditures for 2025 were $36.79 million, up from $22.65 million in 2024, indicating increased investment in growth[27]. - The company operates under a single segment focused on payment processing, utilizing Adjusted EBITDA and Adjusted EBITDA Margin as key performance metrics[20]. - Adjusted EBITDA for 2025 is not explicitly stated but is a critical measure for evaluating financial performance before certain expenses[21]. Customer and Revenue Metrics - Total Payments Volume (TPV) is a key operating metric indicating the aggregate value of all payments processed, reflecting the success of global merchants and business growth[28]. - Net Revenue Retention Rate (NRR) is crucial for assessing customer retention and revenue growth, calculated by comparing current period revenue to prior period revenue from the same customers[29]. - The top 10 customers accounted for 61% of the company's revenues in 2025, with two customers individually representing over 10% of total revenues[73]. - Merchant attrition or a decline in clients' growth rates could lead to a decrease in revenues, impacting operating margins and financial condition[68]. - The company’s growth has been partially driven by the growth of its clients' businesses, and any slowdown in this growth could adversely affect transaction volumes and operating margins[69]. Strategic Outlook and Growth - The company emphasizes the importance of adapting to technological changes and competition in the payments processing industry as part of its strategic outlook[38]. - Future growth strategies include expanding into new products and markets, as well as pursuing strategic acquisitions[38]. - The company is experiencing significant expansion and anticipates continued growth to address potential increases in its customer base and market opportunities[63]. - The company may expand into new industry verticals and geographic regions, but faces risks associated with regulatory compliance and potential reputational concerns[95]. Competition and Market Risks - The company is subject to substantial competition in the payment services market, which may intensify as new entrants and existing competitors enhance their offerings[54]. - The company relies on a significant share of revenue from large merchants, and any reduction in business with these merchants could materially harm its financial performance[46]. - The company faces challenges in managing multiple commercial relationships, which could lead to execution problems affecting revenues and operating margins[66]. Regulatory and Compliance Risks - The company’s financial statements are prepared in accordance with IFRS, ensuring compliance with international accounting standards[17]. - The company operates in a complex regulatory environment, which may lead to increased scrutiny and potential legal claims if compliance is not maintained[91]. - The company is licensed and regulated in multiple jurisdictions, including the EU, UK, and various countries in Latin America, with ongoing efforts to obtain additional licenses in emerging markets[90]. - Compliance with payment network and card scheme rules is essential, as violations could lead to penalties or suspension of services[134]. - Regulatory compliance is critical, as failure to adhere to anti-money laundering and anti-corruption laws could result in significant penalties and reputational harm[144]. Cybersecurity and Operational Risks - The company is subject to cyberattacks and data breaches, which could adversely affect its reputation and financial condition[49]. - The company experienced a cybersecurity breach in 2019, resulting in a loss of approximately US$516 thousand due to fraudulent cash withdrawals[79]. - The company expects to expend significant additional resources to protect against security or privacy breaches and maintain compliance with evolving data protection laws[82]. - The company must continuously improve its fraud-prevention measures to mitigate risks associated with illegal or improper uses of its platform[145]. - The company faces increasing risks from sophisticated fraudulent activities, which could lead to reputational damage and financial losses[140]. Economic and Political Risks - The company operates in multiple emerging markets, particularly in Latin America, exposing it to political, regulatory, and economic risks[49]. - Economic and political risks, including conflicts and sanctions, could negatively impact consumer spending and, consequently, the company's revenue and profits[123]. - The ongoing war between Russia and Ukraine has led to increased energy prices and inflation, which may adversely affect macroeconomic conditions globally[124]. - Political and social unrest in Brazil and Argentina could adversely affect the company's business and financial condition due to high revenue concentration in these markets[192][188]. Currency and Tax Risks - The company is exposed to currency risk, particularly with currencies like the Argentine peso and Brazilian real, which have historically experienced significant devaluations[99]. - Changes in tax laws and regulations could adversely impact the company's effective tax rate and financial condition, particularly with the OECD's Pillar Two framework introducing a global minimum corporate tax rate of 15% starting January 2027[113]. - The company may face increased tax costs due to transfer pricing rules and challenges from tax authorities regarding intra-group transactions[114]. Internal Control and Management Risks - The company’s internal controls and compliance mechanisms are still under development, which may leave it vulnerable to regulatory risks and operational inefficiencies[64]. - The company relies on manual processes for various operations, increasing the risk of errors and control deficiencies, particularly in treasury and accounting functions[155]. - The company is dependent on key personnel, and the loss of senior executives could materially affect its business[179]. Litigation and Reputational Risks - The company is currently involved in litigation, including a class action filed on October 6, 2023, alleging misstatements related to foreign exchange control risks in Argentina[172]. - The company faces reputational risks associated with its former operations as a division of AstroPay, which could impact its business[174]. - The company believes that a significant portion of class action securities claims is due to negative publicity from a short seller, with the first claim filed on February 23, 2023[170].

Market Potential - The total addressable market for the Swoop® system device placements in the United States is estimated to exceed $16 billion[23]. - The company targets over 9,600 potential care sites in the U.S., including 4,000 critical care units and 5,600 emergency departments, for the deployment of the Swoop® system[60]. - The total addressable market for the Swoop® system device placements in the United States is estimated to exceed $16 billion, indicating significant growth potential in an underpenetrated market[73]. Product Overview - The Swoop® system is the first FDA-cleared portable ULF MR brain imaging system, designed for use in various healthcare settings, including ICUs and emergency departments[24]. - The Swoop® system operates at an ultra-low field strength of 0.064T, significantly lower than the 1.5T or higher field strength of conventional MRI scanners, allowing for portability and ease of use[86]. - The Swoop® system is designed to deliver diagnostic-quality images with higher contrast resolution than other portable brain imaging systems, improving diagnostic capabilities[92]. - The Swoop® system's design allows for bedside imaging, reducing the risk of patient transport injuries, which occur in 26-79% of critically ill patients[54]. - The system's design allows for bedside scanning, improving patient experience and reducing anxiety compared to traditional MRI procedures[99]. Technological Advancements - The ninth-generation AI-powered Swoop® system software received FDA clearance in July 2024, which reduces scan times without compromising image quality[26]. - The tenth-generation Optive AI™ software, cleared in May 2025, enhances image processing stages, resulting in greater clarity and detail[27]. - The technology includes AI-powered noise-cancellation to mitigate electromagnetic interference, which is a common issue with conventional MRI systems[90]. - The Swoop® system integrates with PACS for seamless image sharing and can also utilize a secure cloud-based PACS for remote access, enhancing patient care[96]. Cost Efficiency - The Swoop® system is significantly more affordable than conventional MRI and CT scanners, making it accessible for healthcare facilities with limited financial resources[52]. - The average cost of conventional MRI scanners ranges from $1.2 million to $3 million, making the Swoop® system a more affordable alternative[78]. - The Swoop® system has demonstrated an average cost saving of $590 per patient in MR-compatible supplies and reduced MRI wait times by approximately 18 hours, enhancing operational efficiency in hospitals[59]. Regulatory Approvals - The Swoop® system has received marketing authorization in multiple countries, including the EU, UK, Canada, Australia, New Zealand, and India[30]. - The company received 510(k) clearance from the FDA for its ninth-generation AI-powered Swoop® system software in July 2024, and for its tenth-generation Optive AI™ software in May 2025[162]. - The company obtained CE Mark and UKCA Mark approvals for its ninth-generation software in October 2024 and February 2025, respectively, and for Optive AI™ software in August 2025[162]. - The first-generation Swoop® system received regulatory approval in India from the CDSCO in December 2025, allowing for commercialization throughout India[162]. Clinical Value - The company has initiated several clinical studies, including ACTION PMR, which demonstrated the Swoop® system's ability to identify small strokes rapidly and reliably, reinforcing its clinical value[69]. - The Swoop® system is strategically positioned to improve patient access and convenience by enabling in-office brain imaging, thus enhancing patient satisfaction and clinical decision-making[67]. - The system's operation can reduce emergency department time to scan from 27.7 hours for conventional MRI to a median of 2.5 hours[55]. Business Model and Strategy - The Swoop® system's sales model includes ownership with an annual software, service, and support agreement, which is expected to improve gross margins as adoption increases[61]. - The company has launched PULSE, a subscription-based platform for users of the Swoop® system, aimed at facilitating ongoing innovation and potential expansion into new imaging applications[65]. - The company plans to expand its international presence through partnerships with distributors across Europe, Asia Pacific, and the Middle East, aiming to serve more clinicians and patients globally[71]. Financial Performance - The company incurred net losses of $35.6 million and $40.7 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $330.0 million as of December 31, 2025[212]. - The company has generated limited revenue from product sales to date and has not achieved wide market acceptance for its products[213]. - The company may need to raise additional capital to fund commercialization plans, including manufacturing, sales, and marketing activities[215]. Compliance and Regulatory Challenges - Medical devices must undergo pre-market review and receive clearance or approval from the FDA prior to commercialization, with most new devices classified as Class II or III requiring significant user fees[141]. - The company must comply with post-market regulatory requirements, including reporting device-related deaths and serious injuries within 10 days[163]. - The company is required to submit a diversity action plan for pivotal clinical trials to the FDA, which includes enrollment goals and a rationale for those goals[161]. Risks and Uncertainties - The company has encountered risks and uncertainties typical for growing companies in emerging industries[214]. - The company may seek additional capital through various financing methods, including debt and equity financings[215]. - Future financing may not be available in sufficient amounts or acceptable terms, potentially affecting stockholder rights and market price of Class A common stock[216].

Five Below, Inc. Announces Fourth Quarter and Fiscal 2025 Financial Results NEWS RELEASE Q4 Net Sales Increase of 24.3% to $1.73 Billion; Q4 Comparable Sales Increase of 15.4% FY 2025 Net Sales Increase of 22.9% to $4.76 Billion; FY 2025 Comparable Sales Increase of 12.8% Q4 GAAP Diluted EPS Increase of 26.3% to $4.28, Q4 Adjusted Diluted EPS Increase of 23.9% to $4.31 FY 2025 GAAP Diluted EPS Increase of 40.7% to $6.47, FY 2025 Adjusted Diluted EPS Increase of 32.3% to $6.67 Provides First Quarter and Fisc ...